HRP20030050B1 - Sustained-release preparations of quinolone antibiotics and method for preparation thereof - Google Patents

Sustained-release preparations of quinolone antibiotics and method for preparation thereof

Info

Publication number
HRP20030050B1
HRP20030050B1 HR20030050A HRP20030050A HRP20030050B1 HR P20030050 B1 HRP20030050 B1 HR P20030050B1 HR 20030050 A HR20030050 A HR 20030050A HR P20030050 A HRP20030050 A HR P20030050A HR P20030050 B1 HRP20030050 B1 HR P20030050B1
Authority
HR
Croatia
Prior art keywords
sustained
preparation
release preparations
quinolone antibiotics
mixture
Prior art date
Application number
HR20030050A
Other languages
English (en)
Croatian (hr)
Inventor
Kanikanti Venkata-Rangarao
Rupp Roland
Weber Wolfgang
Deuringer Peter
Henck Jan-Olav
Stass Heino
Takaaki Nishioka
Katakawa Yoshifumi
Taniguchi Chika
Ichihashi Hitoshi
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of HRP20030050A2 publication Critical patent/HRP20030050A2/hr
Publication of HRP20030050B1 publication Critical patent/HRP20030050B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HR20030050A 2000-06-26 2003-01-24 Sustained-release preparations of quinolone antibiotics and method for preparation thereof HRP20030050B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10031043A DE10031043A1 (de) 2000-06-26 2000-06-26 Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
PCT/EP2001/006695 WO2002000219A1 (de) 2000-06-26 2001-06-13 Retard-zubereitungen von chinolon-antibiotika und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
HRP20030050A2 HRP20030050A2 (en) 2004-06-30
HRP20030050B1 true HRP20030050B1 (en) 2011-07-31

Family

ID=7646816

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030050A HRP20030050B1 (en) 2000-06-26 2003-01-24 Sustained-release preparations of quinolone antibiotics and method for preparation thereof

Country Status (41)

Country Link
US (3) US7709022B2 (bg)
EP (1) EP1296685B1 (bg)
JP (1) JP4958373B2 (bg)
KR (1) KR100939617B1 (bg)
CN (1) CN1273138C (bg)
AR (1) AR029688A1 (bg)
AT (1) ATE355062T1 (bg)
AU (1) AU2001270573A1 (bg)
BG (1) BG65914B1 (bg)
BR (1) BRPI0111911B8 (bg)
CA (1) CA2414271C (bg)
CU (1) CU23264B7 (bg)
CY (1) CY1107574T1 (bg)
CZ (1) CZ301812B6 (bg)
DE (2) DE10031043A1 (bg)
DK (1) DK1296685T3 (bg)
DO (1) DOP2001000199A (bg)
EE (1) EE04992B1 (bg)
ES (1) ES2282270T3 (bg)
GT (1) GT200100126A (bg)
HK (1) HK1058479A1 (bg)
HN (1) HN2001000132A (bg)
HR (1) HRP20030050B1 (bg)
HU (1) HU229806B1 (bg)
IL (2) IL153333A0 (bg)
MA (1) MA25761A1 (bg)
MX (1) MXPA02012727A (bg)
MY (1) MY140994A (bg)
NO (1) NO325415B1 (bg)
NZ (1) NZ523352A (bg)
PE (1) PE20020207A1 (bg)
PL (1) PL203710B1 (bg)
PT (1) PT1296685E (bg)
RU (1) RU2332204C2 (bg)
SI (1) SI1296685T1 (bg)
SK (1) SK287384B6 (bg)
SV (1) SV2002000505A (bg)
TW (1) TWI279232B (bg)
UA (1) UA83616C2 (bg)
WO (1) WO2002000219A1 (bg)
ZA (1) ZA200210350B (bg)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US7491768B2 (en) * 2002-06-25 2009-02-17 Woong-Sig Moon Polymer resin formulation having anti-microbial or anti-coagulability and preparation method thereof
BRPI0407368A (pt) * 2003-02-10 2006-02-14 Bayer Healthcare Ag tratamento de doenças bacterianas dos órgãos respiratórios mediante aplicação local e fluor-quinolonas.
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
US7278982B2 (en) 2003-03-27 2007-10-09 Bioactis Limited Powder medicine applicator for nasal cavity
EP1652522A4 (en) * 2003-08-04 2008-11-26 Kyorin Seiyaku Kk PROLONGED RELEASE TABLET FOR ORAL ADMINISTRATION
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2006007323A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
US20080206329A1 (en) * 2004-12-03 2008-08-28 Sanjay Verma Modified Release Ciprofloxacin Compositions
PT1868581E (pt) * 2005-04-11 2012-06-22 Abbott Lab Composições farmacêuticas que possuem perfis de dissolução melhorados para fármacos pouco solúveis
ATE460934T1 (de) * 2006-07-19 2010-04-15 Tabuk Pharmaceutical Mfg Co Pharmazeutische zubereitungen von ciprofloxacin
WO2008078730A1 (ja) 2006-12-26 2008-07-03 Translational Research, Ltd. 経鼻投与用製剤
NZ588695A (en) * 2008-03-21 2012-11-30 Mylan Pharmaceuticals Inc Extended release forumulation containing a wax and ciprofloxacin
PL2395840T3 (pl) * 2009-02-13 2020-09-07 Romark Laboratories, L.C. Preparaty farmaceutyczne nitazoksanidu o kontrolowanym uwalnianiu
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
US11033624B2 (en) * 2010-06-02 2021-06-15 Novaflux Inc. Medical item for prevention and treatment of ear infection
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
US10285865B2 (en) 2014-05-02 2019-05-14 Novaflux Inc. Drug-releasing device usable in mucosal body cavities
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5286754A (en) * 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
WO1999015172A1 (de) * 1997-09-25 1999-04-01 Bayer Aktiengesellschaft Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
US6261601B1 (en) * 1997-09-19 2001-07-17 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951792A (en) * 1959-11-18 1960-09-06 Smith Kline French Lab Sustained release pharmaceutical tablets
FR2100858B1 (bg) 1970-07-03 1975-06-06 Daiichi Seiyaku Co
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3142854A1 (de) 1981-10-29 1983-05-11 Bayer Ag, 5090 Leverkusen 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-piperazino-chinolin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4370313A (en) * 1981-10-26 1983-01-25 Eaton Laboratories, Inc. Nitrofurantoin dosage form
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4530928A (en) * 1982-01-13 1985-07-23 Merck & Co., Inc. Quinoline carboxylic acid complexes with guanidinium carbonate
US4440740A (en) * 1982-04-26 1984-04-03 Merck & Co., Inc. α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption
IT1198386B (it) 1982-07-06 1988-12-21 Lepetit Spa Un prodotto a rilascio protratto contenente il suloctidile
IL70071A (en) 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4639458A (en) * 1985-01-22 1987-01-27 Merck & Co., Inc. Tablet and formulation
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US5188840A (en) * 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
ATE71293T1 (de) 1986-09-18 1992-01-15 London Pharmacy Innovation Arzneiformulierung.
US4869908A (en) * 1987-01-09 1989-09-26 K.V. Pharmaceutical Co. Fibre formulations
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
JP2958731B2 (ja) * 1992-02-14 1999-10-06 日本特殊陶業株式会社 酸化アルミニウム基焼結体及びその製造方法
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
JP2686215B2 (ja) 1993-04-28 1997-12-08 信越化学工業株式会社 徐放性錠剤
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
CN1048628C (zh) 1995-07-06 2000-01-26 东北制药总厂 环丙沙星注射液的制备方法
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
CA2290624C (en) * 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
PA8466701A1 (es) * 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino
WO2000015198A1 (en) 1998-09-14 2000-03-23 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control
EP1790334A3 (en) 1999-11-02 2008-02-20 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6780057B2 (en) * 2001-12-21 2004-08-24 Intel Corporation Coaxial dual pin sockets for high speed I/O applications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5286754A (en) * 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
US6261601B1 (en) * 1997-09-19 2001-07-17 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control
WO1999015172A1 (de) * 1997-09-25 1999-04-01 Bayer Aktiengesellschaft Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung

Also Published As

Publication number Publication date
US20040024018A1 (en) 2004-02-05
EE200200707A (et) 2004-08-16
HN2001000132A (es) 2001-09-11
CZ301812B6 (cs) 2010-06-30
CN1438889A (zh) 2003-08-27
BG107372A (bg) 2003-09-30
CY1107574T1 (el) 2013-03-13
PE20020207A1 (es) 2002-04-27
HUP0300953A2 (hu) 2003-08-28
HU229806B1 (en) 2014-07-28
SK287384B6 (sk) 2010-08-09
US7780986B2 (en) 2010-08-24
SK18212002A3 (sk) 2003-04-01
PT1296685E (pt) 2007-05-31
PL203710B1 (pl) 2009-11-30
ES2282270T3 (es) 2007-10-16
US20070237824A1 (en) 2007-10-11
CA2414271A1 (en) 2002-12-23
JP2004504278A (ja) 2004-02-12
CZ20024216A3 (cs) 2003-04-16
IL153333A0 (en) 2003-07-06
US8187632B2 (en) 2012-05-29
IL153333A (en) 2010-05-31
US20070065509A1 (en) 2007-03-22
KR20030023883A (ko) 2003-03-20
BR0111911A (pt) 2003-05-13
SV2002000505A (es) 2002-12-02
WO2002000219A1 (de) 2002-01-03
DOP2001000199A (es) 2002-05-15
TWI279232B (en) 2007-04-21
DK1296685T3 (da) 2007-05-07
CU23264B7 (es) 2008-03-14
BRPI0111911B1 (pt) 2015-08-25
US7709022B2 (en) 2010-05-04
HUP0300953A3 (en) 2009-04-28
MXPA02012727A (es) 2003-05-14
CN1273138C (zh) 2006-09-06
JP4958373B2 (ja) 2012-06-20
BRPI0111911B8 (pt) 2021-05-25
MY140994A (en) 2010-02-12
DE50112123D1 (de) 2007-04-12
NO20026160L (no) 2002-12-20
EP1296685A1 (de) 2003-04-02
ATE355062T1 (de) 2006-03-15
NZ523352A (en) 2004-08-27
PL360632A1 (en) 2004-09-20
KR100939617B1 (ko) 2010-02-01
DE10031043A1 (de) 2002-02-14
MA25761A1 (fr) 2003-04-01
AR029688A1 (es) 2003-07-10
HK1058479A1 (en) 2004-05-21
BG65914B1 (bg) 2010-05-31
AU2001270573A1 (en) 2002-01-08
EE04992B1 (et) 2008-04-15
HRP20030050A2 (en) 2004-06-30
SI1296685T1 (sl) 2007-06-30
EP1296685B1 (de) 2007-02-28
ZA200210350B (en) 2004-02-10
UA83616C2 (uk) 2008-08-11
CA2414271C (en) 2005-09-27
NO20026160D0 (no) 2002-12-20
GT200100126A (es) 2002-01-31
RU2332204C2 (ru) 2008-08-27
NO325415B1 (no) 2008-04-21

Similar Documents

Publication Publication Date Title
HRP20030050B1 (en) Sustained-release preparations of quinolone antibiotics and method for preparation thereof
AU2001237525A1 (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
AU2001237526A1 (en) Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
ZA200206905B (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same.
IL151209A0 (en) Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
HUP0400636A3 (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
HUP0300207A3 (en) 1,2,3,4-tetrahydroisquinoline derivatives, pharmaceutical compositions containing them and their preparation processes
AU2002255077A1 (en) Derivatives of N-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
AU2002239397A1 (en) Drug formulation having improved oral tolerability
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
AU2001235737A1 (en) Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
AU2002212395A1 (en) Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
PT1210119E (pt) Composicoes farmaceuticas para administracao oral e topica
AU2002217229A1 (en) Pharmaceutical dronedarone composition for parenteral administration
AU2001292331A2 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2001292331A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
IL159219A0 (en) Pyrrolidine oxadiazole derivatives, their preparation and pharmaceutical compositions containing them
IL154966A0 (en) Sulfonamide derivatives, their preparation and pharmaceutical compositions containing them
BR0011300A (pt) Formas cristalinas de um antibiótico macrólido
AU3560601A (en) Novel isoquinoline derivatives, preparation method and pharmaceutical compositions containing them
AU2002360117A1 (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
AU2002341555A1 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration

Legal Events

Date Code Title Description
A1OB Publication of a patent application
PPPP Transfer of rights

Owner name: BAYER HEALTHCARE AG, DE

ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: BAYER PHARMA AG, DE

PPPP Transfer of rights

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190528

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200601

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20210613